Pilot to scale
The pilot is a learning system, not a showcase. It tests a defined adoption hypothesis, codifies what works and creates the governance needed for controlled scale-up.
Programme architecture
Each stage answers a different executive question: where adoption breaks, what should change and whether the model can travel beyond the first clinics.
Build an evidence-based view of how premium decisions are actually made in the target market — where the product enters the journey, where value is lost and how clinics experience the current support model.
Translate clinical differentiation into patient-relevant value, honest trade-off language and a communication structure that commercial teams and clinics can use without overclaiming.
Apply the model in selected clinics, align the field and clinic teams, measure early indicators and turn what works into a practical market-level growth playbook.
Transfer and scale
A pilot that meets the agreed indicators should not remain dependent on one external advisor or one flagship account.
Once agreed pilot indicators are met, turn the working model into a market playbook: target-account criteria, roles, consultation logic, tools, implementation checkpoints and measurement definitions.
Prepare internal trainers and application specialists to introduce, support and assess the model, with shared materials adapted to the local language and compliance context.
Roll out to the next clinic cohort, compare the same indicators and use field learning to refine the playbook before wider market or regional expansion.
Transfer package
Market playbook · trainer package · implementation materials · assessment standard · measurement loop
The result is an operating model the brand can own and govern, without permanent dependence on external headcount. Clinical recommendations remain with the surgeon and patient decisions remain with the patient.
Governance
The rollout logic is agreed before expansion, not improvised after a promising pilot.
Pilot clinics are selected against explicit criteria. Baseline and follow-up indicators use the same definitions. The next cohort receives a version of the model that reflects both the original design and what the field has learned.
Local language, compliance requirements, clinic economics and team capability are treated as design constraints. A result in one clinic is not presented as proof that every market will respond identically.
Commercial performance is separated from clinical efficacy. The programme supports patient understanding and adoption; it does not replace the surgeon's clinical recommendation or promise a patient outcome.
Start the conversation
Tell me about the product, market and adoption challenge you need to solve.
